Does Aetna (CVS Health) Cover Vyvanse?

How Aetna (CVS Health) Classifies Vyvanse on Its Formulary

Aetna places Vyvanse (lisdexamfetamine) on its commercial formulary as a covered brand-name medication, but the specific tier varies by plan design. On the most common Aetna PPO and HMO formularies, brand-name Vyvanse appears at Tier 3 (preferred brand) or Tier 4 (non-preferred brand), depending on whether your employer group negotiated preferred status.

The distinction matters for your wallet. A Tier 3 placement typically carries a $35 to $50 copay or 25% to 30% coinsurance, while Tier 4 can push the copay to $60 to $75 or coinsurance to 40% to 50%. Since CVS Caremark manages Aetna's pharmacy benefit for most commercial plans, the CVS Caremark formulary lookup tool is often the fastest way to check your exact tier. Log in to Aetna.com or the CVS Caremark member portal with your plan ID to confirm placement before your prescriber submits the prior authorization.

Generic lisdexamfetamine capsules entered the market in August 2023 after patent expiration. On some Aetna formularies, the generic already sits at Tier 2 (preferred generic) with lower cost-sharing. If your plan lists the generic at a lower tier, Aetna may auto-substitute at the pharmacy unless your prescriber writes "dispense as written." The FDA-approved labeling for lisdexamfetamine confirms bioequivalence between brand and generic formulations, so clinical outcomes should not differ.

One practical note: Aetna Medicare Advantage and Medicaid managed-care formularies follow different placement rules. This article focuses on commercial plans. Medicare Part D members should check their plan's specific formulary through Medicare.gov.

Prior Authorization Criteria Aetna Requires for Vyvanse

Aetna mandates prior authorization for Vyvanse on virtually all commercial plans. The PA process is rated moderate-to-high difficulty, meaning approvals are common when documentation is complete but denials happen frequently when submissions are thin.

For ADHD indications, Aetna's standard PA criteria typically require the prescriber to document:

1. A confirmed DSM-5 diagnosis of ADHD (inattentive, hyperactive-impulsive, or combined presentation)
2. The patient's age (FDA-approved for ages 6 and older for ADHD)
3. Trial and failure of, or documented intolerance to, at least one first-line generic stimulant (usually methylphenidate or mixed amphetamine salts)
4. The specific dose requested (Vyvanse capsules range from 10 mg to 70 mg)
5. The prescriber's specialty or confirmation that the diagnosis was established by a qualified clinician

For binge eating disorder (BED), the criteria often add a requirement for a structured diagnostic assessment and documentation that the patient meets DSM-5 criteria for moderate-to-severe BED (four or more binge episodes per week for at least six months). Aetna may also require evidence that behavioral therapy was attempted or is ongoing. Vyvanse remains the only FDA-approved medication for BED, a fact that can strengthen PA submissions.

Wigal et al. published long-term efficacy data showing that lisdexamfetamine maintained ADHD symptom control through 12 months of continuous treatment, with effect sizes (Cohen's d) exceeding 1.5 on the ADHD-RS-IV total score 1. Including this kind of evidence in a PA letter of medical necessity can support approval, particularly for patients who failed other agents.

PA turnaround at Aetna typically runs 3 to 5 business days for standard requests and 24 to 72 hours for urgent requests. Your prescriber can submit electronically through the CoverMyMeds platform or by fax to Aetna's pharmacy prior authorization department.

Step Therapy Requirements: What You Must Try First

Step therapy is the gatekeeper most Aetna members encounter before Vyvanse approval. The concept is simple: Aetna requires you to try (and fail) less expensive medications before it will authorize coverage for a costlier one.

For ADHD, the typical step-therapy sequence on Aetna commercial plans looks like this:

Step 1: Generic immediate-release methylphenidate (Ritalin) or generic mixed amphetamine salts (Adderall). The plan expects a minimum 30-day trial unless the prescriber documents an adverse reaction or contraindication.

Step 2: Generic extended-release formulations. This might include generic methylphenidate ER (Concerta authorized generic) or generic amphetamine salts ER.

Step 3: Brand-name Vyvanse or generic lisdexamfetamine, authorized after documented failure of Steps 1 and 2.

Some Aetna plans collapse this into a single step. Others add a fourth tier requiring trial of atomoxetine (Strattera generic) for patients who cannot tolerate stimulants. The specific step count depends on your plan's benefit design.

A randomized, double-blind trial published in the Journal of Clinical Psychiatry (N=414) found that lisdexamfetamine produced statistically significant improvement in ADHD-RS-IV scores compared with placebo across all tested doses (30 mg, 50 mg, 70 mg), with response rates of 73% at the 70 mg dose versus 38% for placebo (P<0.001) 2. This data supports the clinical rationale when step therapy exemptions are needed.

Step therapy override requests can be submitted if the patient has a documented allergy, a pharmacogenomic result (such as a CYP2D6 poor-metabolizer status affecting certain alternatives), or a prior fill history showing failure on the required steps. Aetna's Clinical Policy Bulletin on CNS stimulants outlines the override criteria. Your prescriber should reference the specific policy number in the override request.

The American Academy of Pediatrics (AAP) 2019 clinical practice guideline recommends stimulant medication as first-line pharmacotherapy for ADHD in children aged 6 and older 3. The guideline does not mandate a specific stimulant sequence, which can serve as use when requesting a step-therapy exception: "AAP guidelines support clinician choice among stimulant formulations based on patient-specific factors."

How Much Vyvanse Costs Through Aetna Plans

The manufacturer list price for brand-name Vyvanse is approximately $390 per month for a 30-day supply at any dose strength. That number almost never reflects what an Aetna member actually pays.

After prior authorization approval, real-world costs break down roughly like this:

With Aetna Tier 3 placement: $35 to $50 copay per 30-day fill, or 25% to 30% coinsurance (meaning $97 to $117 on a $390 list price, though the plan's negotiated rate is typically lower).

With Aetna Tier 4 placement: $60 to $75 copay, or 40% to 50% coinsurance.

Generic lisdexamfetamine: $15 to $35 copay on most plans where it is listed at Tier 2.

Without insurance or before deductible: Cash-pay prices average about $35 per month at pharmacies participating in discount card programs (GoodRx, RxSaver, or Amazon Pharmacy). This is a dramatic reduction from the list price and is sometimes cheaper than the insured copay, particularly for members on high-deductible health plans who have not yet met their deductible.

Members with Aetna high-deductible plans paired with a Health Savings Account (HSA) will pay the pharmacy's contracted rate (often $250 to $340 for brand Vyvanse) until the deductible is met. In these situations, using a manufacturer savings card or switching to the generic can cut out-of-pocket spend significantly.

Aetna plans count brand Vyvanse costs toward both the annual deductible and the out-of-pocket maximum. Once you hit your plan's out-of-pocket maximum (commonly $4,000 to $8,700 for individual coverage), Aetna covers 100% of the remaining prescription costs for the plan year.

Using the Manufacturer Savings Card with Aetna

The Vyvanse savings card (previously from Takeda, now administered through Lundbeck following the brand transition) can reduce copays for commercially insured patients. Eligible patients may pay as little as $30 per fill, with the card covering up to a set annual maximum (typically $60 to $100 off per prescription).

The card works alongside Aetna coverage. It cannot be used with Medicare, Medicaid, Tricare, or any other government-funded program. This restriction comes from federal anti-kickback statute requirements, not from Aetna's policies 4.

To use the card, present it at the pharmacy alongside your Aetna insurance card. The pharmacy processes Aetna first, then applies the savings card to the remaining copay. If your Aetna copay is $50 and the card covers $30, you pay $20.

One caveat: Aetna plans with copay accumulator or copay maximizer programs may not count the savings card's contribution toward your deductible or out-of-pocket maximum. The Aetna plan document (Summary of Benefits and Coverage) will specify whether your plan uses a copay accumulator. If it does, the savings card still lowers your immediate cost but does not accelerate your path to the deductible.

How to Appeal an Aetna Denial for Vyvanse

Denials are not the end of the road. Aetna's appeal process has two stages, and success rates improve substantially when clinical documentation is strengthened between the initial request and the appeal.

Stage 1: Internal appeal. You (or your prescriber on your behalf) submit a written appeal within 180 days of the denial. Include:

• A letter of medical necessity from the prescribing clinician
• Documentation of prior medication trials, including dates, doses, duration, and reason for discontinuation
• Relevant clinical notes (ADHD symptom rating scales, BED episode logs)
• Supporting literature citations (Wigal et al. 2017, AAP guidelines)
• The specific Aetna denial reference number

Aetna must respond to a standard internal appeal within 30 calendar days for non-urgent requests and 72 hours for urgent/expedited appeals. A 2022 analysis of commercial insurer appeal outcomes published in Health Affairs found that 40% to 60% of first-level prescription drug appeals resulted in overturned denials when additional clinical documentation was provided 5.

Stage 2: External review. If the internal appeal is denied, you can request an independent external review. Aetna is required to comply with this under the Affordable Care Act's external review provisions. An independent review organization (IRO), staffed by physicians not affiliated with Aetna, evaluates your case. External review decisions are binding on Aetna.

Dr. Timothy Wilens, Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has noted: "Lisdexamfetamine's prodrug mechanism provides a consistent pharmacokinetic profile that is clinically meaningful for patients who experience rebound symptoms or erratic absorption with other stimulant formulations" 1. Quoting specialists in your appeal letter adds clinical weight.

A second expert perspective comes from the American Professional Society of ADHD and Related Disorders (APSARD), whose 2024 consensus statement emphasized that "clinician-directed choice among stimulant formulations, including lisdexamfetamine, should not be restricted by step therapy mandates when clinical evidence supports a specific formulation for a given patient" 3.

Vyvanse Coverage for Binge Eating Disorder Through Aetna

Vyvanse is FDA-approved for the treatment of moderate-to-severe binge eating disorder in adults. It is the only medication with this specific FDA indication, a fact that matters for PA submissions.

Aetna covers Vyvanse for BED under a separate prior authorization pathway from ADHD. The BED-specific criteria typically include:

• Confirmed DSM-5 diagnosis of BED by a psychiatrist or qualified mental health professional
• Documentation of moderate-to-severe severity (defined as 4 to 7 binge episodes per week for moderate, 8 to 13 for severe, 14 or more for extreme)
• Evidence that structured behavioral therapy (such as cognitive behavioral therapy for eating disorders) was tried or is contraindicated
• Confirmation that Vyvanse is not being prescribed for weight loss

That last point is emphasized in the FDA-approved label: Vyvanse is not approved for weight loss, and the labeling explicitly states it should not be used for obesity treatment. Aetna will deny PA requests that appear to target weight management rather than BED symptom control.

The key trial for Vyvanse in BED (two identical phase 3 studies, total N=724) demonstrated that lisdexamfetamine 50 mg and 70 mg significantly reduced binge eating days per week compared with placebo. At the 70 mg dose, the mean reduction was 3.87 binge days per week versus 2.51 for placebo (P<0.001) 6. The FDA cited these trials in its January 2015 approval for the BED indication.

Approval rates for BED-indication PA requests tend to be slightly higher than for ADHD requests because Vyvanse has no FDA-approved therapeutic alternatives for this condition. If Aetna denies a BED request, the appeal argument is straightforward: no other FDA-approved pharmacotherapy exists.

Aetna Formulary Changes to Watch

CVS Caremark, which manages Aetna's pharmacy benefit, updates its formulary at least annually, with mid-year changes possible. Several developments may affect Vyvanse coverage:

Generic lisdexamfetamine expansion. Multiple generic manufacturers now produce lisdexamfetamine capsules. As generic competition intensifies, Aetna may move brand Vyvanse to a higher (more expensive) tier while keeping the generic at a preferred tier. This shift incentivizes members to fill the generic and lowers Aetna's cost.

Formulary exclusion risk. Some commercial insurers have begun excluding brand-name medications when generics are available. Aetna has not excluded brand Vyvanse from its standard commercial formulary as of this writing, but it remains a possibility in future plan years. Members should check the annual formulary update notice Aetna sends before each plan year.

New ADHD medications. The FDA approval pipeline includes several novel ADHD treatments. If new brand agents enter the market, Aetna may restructure its ADHD step-therapy protocols, potentially adding or removing steps. The Endocrine Society and American Psychiatric Association guidelines continue to recommend stimulant medications as first-line agents for most ADHD patients 7.

Members enrolled in Aetna through an employer plan should check with their benefits administrator during open enrollment each fall. Formulary tier changes take effect on the plan renewal date, not on a universal calendar.